Carbapenem-resistant Enterobacterales (CRE) are a major antimicrobial-resistance concern because these bacteria can resist carbapenems, a class of antibiotics used to treat serious bacterial infections. Understanding how CRE develop resistance, how carbapenemases affect antibiotic activity, and how laboratories identify susceptibility is essential for understanding modern antimicrobial research.
One particularly important resistance mechanism involves New Delhi metallo-beta-lactamase (NDM), an enzyme that can inactivate many beta-lactam antibiotics, including carbapenems.
Aztreonam-avibactam has attracted significant scientific and clinical interest because its two components have complementary roles against certain beta-lactamase mechanisms. Aztreonam is relatively stable against metallo-beta-lactamases, while avibactam inhibits several susceptible serine beta-lactamases that may otherwise compromise aztreonam activity.
This guide explores CRE, common resistance mechanisms, NDM-producing bacteria, diagnostic approaches, antimicrobial susceptibility testing, and the scientific role of aztreonam-avibactam.
What Are Carbapenem-Resistant Enterobacterales?
Enterobacterales are a large order of Gram-negative bacteria that includes organisms associated with both community-acquired and healthcare-associated infections.
Important examples include:
- Escherichia coli
- Klebsiella pneumoniae
- Enterobacter cloacae complex
- Klebsiella oxytoca
- Citrobacter species
Carbapenem-resistant Enterobacterales are organisms that meet the applicable criteria for resistance to one or more carbapenem antibiotics. Some CRE produce carbapenemase enzymes, while others develop resistance through combinations of mechanisms such as reduced outer-membrane permeability and the production of other beta-lactamases.
This distinction matters because not every CRE isolate produces the same resistance enzyme, and not every CRE isolate has the same susceptibility profile.
Accurate organism identification and appropriate laboratory testing help distinguish these mechanisms.
Why Is CRE Resistance a Major Concern?
Carbapenems are important antibiotics in the management of selected serious bacterial infections. Resistance to these drugs can make treatment more complex and may reduce the number of active antimicrobial options.
Several factors contribute to the clinical importance of CRE:
- Production of carbapenemase enzymes.
- Co-production of multiple beta-lactamases.
- Changes in bacterial outer-membrane permeability.
- Alterations in antibiotic targets or other bacterial structures.
- Acquisition and spread of resistance genes.
- Differences in susceptibility between individual bacterial isolates.
CRE can be associated with urinary tract infections, bloodstream infections, pneumonia and intra-abdominal infections, among other clinical conditions.
The significance of an isolate depends on the infection, organism, susceptibility results and patient-specific circumstances. Detection of CRE in a specimen must also be interpreted in the clinical context to distinguish infection from colonization.
What Are Carbapenemases?
Carbapenemases are enzymes that can break down carbapenem antibiotics. They are an important cause of carbapenem resistance in Gram-negative bacteria.
Several clinically important carbapenemase families are discussed in antimicrobial-resistance surveillance and clinical guidance.
1. NDM: New Delhi Metallo-Beta-Lactamase
NDM belongs to the metallo-beta-lactamase family. These enzymes use metal ions at their active sites and can hydrolyze many beta-lactam antibiotics, including carbapenems.
NDM-producing organisms may also carry other beta-lactamase genes, making their overall resistance profile more complicated.
2. KPC: Klebsiella pneumoniae Carbapenemase
KPC is a serine carbapenemase associated with resistance to multiple beta-lactam antibiotics. Its enzyme class differs from that of NDM, which is important when evaluating how different beta-lactamase inhibitors work.
3. OXA-48-Like Carbapenemases
OXA-48-like enzymes are another important family of serine carbapenemases. Their activity and the resistance profiles of organisms carrying them can differ from those associated with other carbapenemases.
4. VIM and IMP Metallo-Beta-Lactamases
VIM and IMP are additional metallo-beta-lactamase families. Like NDM, they can compromise the activity of many beta-lactam antibiotics.
Understanding which enzyme is present can inform the microbiological assessment, but a resistance-gene result alone does not establish susceptibility to a particular antibiotic.
NDM vs KPC: Why the Difference Matters
NDM and KPC can both contribute to carbapenem resistance, but they belong to different beta-lactamase classes.
| Feature | NDM | KPC |
|---|---|---|
| Enzyme class | Metallo-beta-lactamase | Serine beta-lactamase |
| Uses a metal ion at its active site | Yes | No |
| Can hydrolyze carbapenems | Yes | Yes |
| Directly inhibited by avibactam | No | Many KPC enzymes are susceptible to avibactam inhibition |
| Relevance to aztreonam-avibactam | Aztreonam is relatively stable against NDM hydrolysis; avibactam can inhibit susceptible co-produced serine enzymes | Activity depends on the complete resistance profile and susceptibility of the isolate |
This distinction explains why beta-lactamase inhibitors cannot be treated as interchangeable. An inhibitor’s activity against one enzyme family does not mean it directly inhibits every other family.
How Does Aztreonam-Avibactam Work Against Certain Resistant Bacteria?
Aztreonam-avibactam combines two components with complementary functions.
Aztreonam: The antibacterial component
Aztreonam is a monobactam beta-lactam antibiotic. It interferes with bacterial cell-wall synthesis by binding to susceptible penicillin-binding proteins, particularly PBP3.
A key characteristic of aztreonam is its relative stability against hydrolysis by metallo-beta-lactamases such as NDM.
However, aztreonam can still be hydrolyzed by other beta-lactamases, including certain extended-spectrum beta-lactamases (ESBLs) and AmpC enzymes.
Avibactam: The beta-lactamase inhibitor
Avibactam is a non-beta-lactam beta-lactamase inhibitor. It inhibits several susceptible serine beta-lactamases, including many enzymes from classes A and C and certain class D enzymes.
It does not directly inhibit metallo-beta-lactamases such as NDM, VIM or IMP.
Why combine them?
Some resistant bacteria produce an MBL alongside other beta-lactamases. In that situation, aztreonam’s relative stability against MBL hydrolysis and avibactam’s inhibition of susceptible serine beta-lactamases provide a scientific rationale for the combination.
The mechanism can be summarized as follows:
- An MBL such as NDM can hydrolyze many beta-lactams but does not efficiently hydrolyze aztreonam.
- Other beta-lactamases produced by the same organism may still compromise aztreonam.
- Avibactam inhibits several susceptible serine beta-lactamases.
- The combination may therefore retain activity against selected resistant isolates.
This mechanism does not mean that every CRE isolate will be susceptible. Other resistance mechanisms and the organism’s complete susceptibility profile remain important.
For more detail, read Aztreonam-Avibactam: Mechanism of Action Explained.
Is Aztreonam-Avibactam Effective Against All CRE?
No. CRE is a broad category that includes organisms with different resistance mechanisms.
The presence of a carbapenemase gene does not automatically establish whether an isolate will be susceptible to aztreonam-avibactam.
Susceptibility may be influenced by:
- The specific carbapenemase or MBL present.
- Co-produced ESBLs, AmpC enzymes or other beta-lactamases.
- Changes in bacterial permeability.
- Alterations in antibiotic targets.
- Additional acquired resistance mechanisms.
- The bacterial species and individual isolate.
Clinical evidence and recommendations must also be considered in their specific context. Evidence concerning NDM-producing Enterobacterales should not automatically be generalized to every carbapenem-resistant organism or every MBL-producing species.
How Is CRE Diagnosed and Identified?
The laboratory evaluation of suspected CRE can involve several complementary approaches.
1. Bacterial culture and identification
Clinical specimens may be cultured to recover and identify the organism. The significance of the result depends on the specimen, clinical presentation and possibility of colonization.
2. Antimicrobial susceptibility testing
Phenotypic susceptibility testing assesses how an isolate responds to selected antimicrobial agents under standardized laboratory conditions.
Methods may include broth microdilution or disk diffusion, where validated for the relevant organism and antimicrobial agent.
3. Carbapenemase detection
Laboratories may use phenotypic or molecular methods to investigate carbapenemase production.
Molecular testing can identify specific resistance genes, while phenotypic approaches evaluate enzyme activity or antimicrobial susceptibility characteristics.
These approaches provide different types of information and may be complementary.
4. Interpretation of the results
Results should be interpreted using validated methods and the current, applicable criteria. Detecting a resistance gene does not replace susceptibility testing when phenotypic testing is indicated and available.
For a related explanation, see Aztreonam-Avibactam Susceptibility Testing and MIC.
What Is the Role of MIC Testing?
The minimum inhibitory concentration (MIC) is the lowest concentration of an antimicrobial agent that prevents visible bacterial growth under defined laboratory conditions.
MIC testing can support susceptibility interpretation when an appropriate validated method and applicable interpretive criteria are available.
Three principles are important:
- An MIC must be interpreted using the correct criteria for the organism and antimicrobial agent.
- MIC values obtained using different methods should not automatically be treated as interchangeable.
- An in-vitro susceptibility result does not guarantee a successful clinical outcome.
Laboratories should follow current standards and relevant regulatory guidance when performing and interpreting antimicrobial susceptibility testing.
What Does Current Clinical Guidance Say?
The Infectious Diseases Society of America (IDSA) 2026 guidance identifies aztreonam-avibactam and cefiderocol as preferred treatment options for invasive infections caused by NDM-producing Enterobacterales. It also discusses ceftazidime-avibactam combined with aztreonam as an alternative when aztreonam-avibactam is unavailable.
These recommendations apply to defined clinical circumstances and should not be interpreted as a universal recommendation for every CRE infection.
The guidance also emphasizes that clinical outcome data for aztreonam-avibactam in NDM-producing infections remain limited and are derived primarily from small clinical-trial subgroups. Laboratory susceptibility, infection characteristics, patient factors and the current local clinical guidance remain important.
Read the IDSA Guidance on Antimicrobial-Resistant Gram-Negative Infections.
Aztreonam-Avibactam and Meblanios
Aztreonam-avibactam describes a combination of active pharmaceutical components. Meblanios is an AIONIOS Pharma product containing aztreonam and avibactam for injection.
For pharmaceutical readers, it is useful to distinguish the scientific literature on the combination from product-specific information. Product composition, approved indications, administration instructions and other prescribing details must be confirmed using the applicable approved product documentation.
Explore the Meblanios product page for product-specific information.
This educational article does not establish that Meblanios is approved for every CRE infection or that every CRE isolate will be susceptible to it. Product claims must remain consistent with the applicable regulatory and prescribing information.
Frequently Asked Questions
What does CRE stand for?
CRE stands for carbapenem-resistant Enterobacterales, a group of bacteria that meet applicable criteria for resistance to one or more carbapenem antibiotics.
What is the difference between CRE and NDM?
CRE describes a resistance category. NDM is a specific type of metallo-beta-lactamase that can cause carbapenem resistance. Some CRE produce NDM, while others produce different carbapenemases or develop resistance through other mechanisms.
Does avibactam inhibit NDM?
No. Avibactam does not directly inhibit NDM. It inhibits several susceptible serine beta-lactamases that may coexist with NDM in resistant bacteria.
Why is aztreonam combined with avibactam?
Aztreonam is relatively stable against MBL-mediated hydrolysis, but other beta-lactamases may compromise its activity. Avibactam inhibits several susceptible serine beta-lactamases, providing a complementary mechanism.
Is aztreonam-avibactam effective against KPC-producing bacteria?
Susceptibility cannot be inferred from the KPC label alone. The complete resistance profile, validated laboratory results and applicable clinical evidence must be considered.
Can a CRE isolate be resistant to aztreonam-avibactam?
Yes. CRE is a diverse group, and additional resistance mechanisms can affect susceptibility. Testing and interpretation are important.
Why is CRE surveillance important?
Surveillance helps track changes in the prevalence and distribution of resistant organisms, supports infection-prevention activities and informs antimicrobial-resistance research and public-health planning.
Where can I learn more about Meblanios?
Visit the Meblanios product page for available product information. Product-specific clinical and regulatory claims should be checked against the applicable approved documentation.
Conclusion
Carbapenem-resistant Enterobacterales represent a complex antimicrobial-resistance challenge because different organisms can develop resistance through different enzymes and non-enzymatic mechanisms.
Understanding the distinction between NDM, KPC and other carbapenemases helps explain why antimicrobial activity cannot be predicted from the term CRE alone.
Aztreonam-avibactam has a complementary mechanism that is particularly relevant to selected MBL-producing Gram-negative organisms: aztreonam is relatively stable against MBL hydrolysis, while avibactam inhibits several susceptible serine beta-lactamases. Nevertheless, susceptibility is not universal, and laboratory results and clinical evidence must be interpreted in context.
For healthcare professionals, researchers and pharmaceutical readers, combining accurate resistance-mechanism knowledge with validated testing and current clinical guidance is essential to understanding CRE and the evolving science of antimicrobial resistance.
Medical disclaimer: This article is for educational purposes only and does not replace professional medical advice, validated laboratory testing, current clinical guidance or approved product information.